Claim Missing Document
Check
Articles

Found 2 Documents
Search

Clinical application of dendrimer in cancer and COVID-19 therapy: a review Devita, Ninda; Nurfadilah; Siti Khadijah; Ulil Albab Habibah
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2311

Abstract

Dendrimers are nanoparticles with unique characteristics. These characteristics allow these nanoparticles to be widely applied in medicine. It can be used as a therapy for various types of cancer. The dendrimers can also been use an alternative to accelerating the diagnosis and therapy of COVID-19. This review aimed to delve deeper into the myriad clinical applications of dendrimers in the treatment of various cancers and its potential use for the treatment or diagnosis of COVID-19. The databases used for this review were Google Scholar and Science Direct. The inclusion criteria for this review are articles published in 2018-2023. Articles other than the original articles and reviews we excluded from the study. Anticancer formulated in dendrimers have a better ability to eradicate cancer cells in the treatment of breast, colon, lung, prostate, skin, ovarian, and liver cancers compared to ordinary anticancer agents. Dendrimer in vivo, in vitro and phase II clinical trials can be used to deliver miRNA therapy or symptomatic drugs in COVID-19 patients and as vaccine delivery agents. The quality of molecular diagnosis of COVID-19 can also be improved with these nanoparticles. The use of dendrimers can improve the quality of management of cancer and COVID-19 patients.
Kenaikan C-Reactive Protein pada Remaja Gangguan Bipolar: A Systematic Review Ulil Albab Habibah; Satria Akbar Putra Asmara; Purwati, Triyana Indah; Nabila, Nisrina
Sehat Rakyat: Jurnal Kesehatan Masyarakat Vol. 5 No. 2 (2026): Mei 2026
Publisher : Yayasan Pendidikan Penelitian Pengabdian Algero

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.54259/sehatrakyat.v5i2.7236

Abstract

The diagnosis of bipolar disorder (BD) in adolescents is often delayed due to reliance on subjective assessments, necessitating objective biomarkers such as C-reactive protein (CRP) to improve clinical accuracy. This systematic review aims to synthesize the latest findings on the role of CRP levels in adolescents with BD through analysis of various experimental studies. The systematic review was conducted in January 2026 through searches in Embase, PubMed, and ScienceDirect for studies from 2016 to 2025. Selection was performed according to PRISMA. Risk of bias was assessed using JBI Critical Appraisal Tools. A total of four experimental studies with a total of 3298 subjects met the criteria with low to moderate risk of bias. CRP levels in adolescents with Bipolar Disorder were found to be significantly elevated compared to the control group, especially during the symptomatic phase and periods of severe symptoms. CRP levels in adolescents with BD were found to be significantly elevated compared to healthy controls (p<0.001) and the anxiety disorder group, especially during the severe symptomatic phase. Additionally, high initial CRP levels significantly predicted longer recovery times (p=0.009). CRP is an effective state-dependent biomarker to support diagnostic accuracy, predict clinical course, and monitor the risk of cognitive decline in adolescents with BD.